LIVIVO - Search results -

Search results

Result 1 - 10 of total 69

Search options

Article ; Online: Preventing ototoxic hearing loss by inhibiting histone deacetylases.

Layman, W S / Zuo, J

2015 Volume 6, Page(s) e1882

MeSH term(s)	Hearing Loss/drug therapy ; Hearing Loss/epidemiology ; Hearing Loss/prevention & control ; Histone Deacetylase Inhibitors/therapeutic use ; Humans
Chemical Substances	Histone Deacetylase Inhibitors
Language	English
Publishing date	2015-09-10
Publishing country	England
Document type	News
ZDB-ID	2541626-1
ISSN	2041-4889 ; 2041-4889
ISSN (online)	2041-4889
ISSN	2041-4889
DOI	10.1038/cddis.2015.252
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Full text

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- Full text online
- Order with fees

Article ; Online: Gut microbiota mediate the FGF21 adaptive stress response to chronic dietary protein-restriction in mice.

Martin, Anthony / Ecklu-Mensah, Gertrude / Ha, Connie W Y / Hendrick, Gustaf / Layman, Donald K / Gilbert, Jack / Devkota, Suzanne

Nature communications

2021 Volume 12, Issue 1, Page(s) 3838

Abstract: Chronic dietary protein-restriction can create essential amino acid deficiencies and induce metabolic adaptation through the hepatic FGF21 pathway which serves to maintain host fitness during prolonged states of nutritional imbalance. Similarly, the gut ... ...

Abstract	Chronic dietary protein-restriction can create essential amino acid deficiencies and induce metabolic adaptation through the hepatic FGF21 pathway which serves to maintain host fitness during prolonged states of nutritional imbalance. Similarly, the gut microbiome undergoes metabolic adaptations when dietary nutrients are added or withdrawn. Here we confirm previous reports that dietary protein-restriction triggers the hepatic FGF21 adaptive metabolic pathway and further demonstrate that this response is mediated by the gut microbiome and can be tuned through dietary supplementation of fibers that alter the gut microbiome. In the absence of a gut microbiome, we discover that FGF21 is de-sensitized to the effect of protein-restriction. These data suggest that host-intrinsic adaptive pathways to chronic dietary protein-restriction, such as the hepatic FGF21 pathway, may in-fact be responding first to adaptive metabolic changes in the gut microbiome.
MeSH term(s)	Adaptation, Physiological/physiology ; Animals ; Bacteria/classification ; Bacteria/genetics ; Cellulose/administration & dosage ; Cellulose/pharmacology ; Diet, Protein-Restricted ; Dietary Proteins/administration & dosage ; Dietary Proteins/metabolism ; Fibroblast Growth Factors/metabolism ; Gastrointestinal Microbiome/drug effects ; Gastrointestinal Microbiome/physiology ; Insulin/administration & dosage ; Insulin/pharmacology ; Liver/drug effects ; Liver/metabolism ; Male ; Mice, Inbred C57BL ; Population Dynamics ; RNA, Ribosomal, 16S/genetics ; Stress, Physiological/physiology ; Time Factors ; Mice
Chemical Substances	Dietary Proteins ; Insulin ; RNA, Ribosomal, 16S ; fibroblast growth factor 21 ; Fibroblast Growth Factors (62031-54-3) ; Cellulose (9004-34-6)
Language	English
Publishing date	2021-06-22
Publishing country	England
Document type	Journal Article
ZDB-ID	2553671-0
ISSN	2041-1723 ; 2041-1723
ISSN (online)	2041-1723
ISSN	2041-1723
DOI	10.1038/s41467-021-24074-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Association between Surgery, Anesthesia, and Obstetric Workforce and Emergent Surgical and Obstetric Mortality among United States Hospital Referral Regions.

Truche, Paul / Semco, Robert S / Hansen, Nathaniel F / Uribe-Leitz, Tarsicio / Roa, Lina / Allar, Benjamin G / Layman, Ilan B / Bergmark, Regan W / Williams, Wendy / Riviello, Robert / McClain, Craig D / Jarman, Molly P / Cooper, Zara / Meara, John G / Ortega, Gezzer

Annals of surgery

2022 Volume 277, Issue 6, Page(s) 952–957

Abstract: Objective: To determine the association between SAO workforce and mortality from emergent surgical and obstetric conditions within US HR Rs.: Background: SAO workforce per capita has been identified as a core metric of surgical capacity by the Lancet ...

Abstract	Objective: To determine the association between SAO workforce and mortality from emergent surgical and obstetric conditions within US HR Rs. Background: SAO workforce per capita has been identified as a core metric of surgical capacity by the Lancet Commission on Global Surgery, but its utility has not been assessed at the subnational level for a high-income country. Methods: The number of practicing surgeons, anesthesiologists, and obstetricians per capita was estimated for all HRRs using the US Health Resources & Services Administration Area Health Resource File Database. Deaths due to emergent general surgical and obstetric conditions were determined from the Center for Disease Control and Prevention WONDER database. We utilized B-spline quantile regression to model the relationship between SAO workforce and emergent surgical mortality at different quantiles of mortality and calculated the expected change in mortality associated with increases in SAO workforce. Results: The median SAO workforce across all HRRs was 74.2 per 100,000 population (interquartile range 33.3-241.0). All HRRs met the Lancet Commission on Global Surgery lower target of 20 SAO per 100,000, and 97.7% met the upper target of 40 per 100,000. Nearly 2.8 million Americans lived in HRRs with fewer than 40 SAO per 100,000. Increases in SAO workforce were associated with decreases in surgical mortality in HRRs with high mortality, with minimal additional decreases in mortality above 60 to 80 SAO per 100,000. Conclusions: Increasing SAO workforce capacity may reduce emergent surgical and obstetric mortality in regions with high surgical mortality but diminishing returns may be seen above 60 to 80 SAO per 100,000. Trial Registration: N/A.
MeSH term(s)	Female ; Pregnancy ; United States/epidemiology ; Humans ; Anesthesiology ; Workforce ; Anesthesiologists ; Anesthesia ; Surgeons
Language	English
Publishing date	2022-02-17
Publishing country	United States
Document type	Journal Article
ZDB-ID	340-2
ISSN	1528-1140 ; 0003-4932
ISSN (online)	1528-1140
ISSN	0003-4932
DOI	10.1097/SLA.0000000000005421
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uk I Zs.35/1: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Adverse childhood events and cognitive function among young adults: Prospective results from the national longitudinal study of adolescent to adult health.

Hawkins, Misty A W / Layman, Harley M / Ganson, Kyle T / Tabler, Jennifer / Ciciolla, Lucia / Tsotsoros, Cindy E / Nagata, Jason M

Child abuse & neglect

2021 Volume 115, Page(s) 105008

Abstract: ... to Adult Health (Add Health), a prospective cohort investigation of U.S. adolescents followed to adulthood ...

Abstract	Background: Adverse childhood experiences (ACEs) may have lasting impacts on cognition. Objective: To determine if ACE exposure is prospectively associated with cognition in young adults. We hypothesized that deprivation- and threat-type ACEs as well as higher cumulative ACE exposure predict poorer cognition. Participants & setting: Participants were from the National Longitudinal Study of Adolescent to Adult Health (Add Health), a prospective cohort investigation of U.S. adolescents followed to adulthood. Current study participants were 18-24 years old (Wave III), 24-32 years old (Wave IV), and 31-42 years old (Wave V). The maximum Wave IV sample was 12,288 adults; Wave V was 1277 adults. Methods: History of ACEs were assessed at Wave III. Three cognitive indicators were assessed at Wave IV and Wave V using the Rey Auditory Verbal Learning Test (immediate and delayed verbal memory) and the Digit-Span Backward Task (working memory). Results: The deprivation ACE of not-having-basic-needs met was associated with poorer working (β = 0.14, CI Conclusions: Higher ACEs, especially deprivation-type, were prospectively linked to poorer cognition. Early wide-scale screening/tailored treatments addressing ACEs and cognitive function may be warranted.
MeSH term(s)	Adolescent ; Adult ; Adverse Childhood Experiences ; Cognition ; Cohort Studies ; Humans ; Longitudinal Studies ; Prospective Studies ; Young Adult
Language	English
Publishing date	2021-03-08
Publishing country	England
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	799143-5
ISSN	1873-7757 ; 0145-2134
ISSN (online)	1873-7757
ISSN	0145-2134
DOI	10.1016/j.chiabu.2021.105008
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1437: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study.

Ha, Min Jin / Singareeka Raghavendra, Akshara / Kettner, Nicole M / Qiao, Wei / Damodaran, Senthil / Layman, Rachel M / Hunt, Kelly K / Shen, Yu / Tripathy, Debu / Keyomarsi, Khandan

International journal of cancer

2022 Volume 150, Issue 12, Page(s) 2025–2037

Abstract: Cyclin-dependent-kinase-4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) is standard of care for patients with advanced hormone receptor (HR)-positive, HER2-negative breast cancer (BC). The Breast Medical Oncology database at MD Anderson Cancer Center ...

Abstract	Cyclin-dependent-kinase-4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) is standard of care for patients with advanced hormone receptor (HR)-positive, HER2-negative breast cancer (BC). The Breast Medical Oncology database at MD Anderson Cancer Center (MDACC) was analyzed to assess effectiveness of the CDK4/6i palbociclib plus ET compared to ET alone. From a total of 5402 advanced HR+ HER2- BC patients referred to MDACC between 1997 and 2020, we identified eligible patients who received palbociclib in combination with first-line (n = 778) and second-line (n = 410) ET. We further identified "control" patients who received ET alone in the first-line (n = 2452) and second-line (n = 1183) settings. Propensity score matching analysis was conducted to balance baseline demographic and clinical characteristics between palbociclib and control cohorts to assess the effect of palbociclib treatment on progression-free survival (PFS) and overall survival (OS). For propensity-matched-cohort in the first-line setting (n = 708), palbociclib group had significantly longer median PFS (17.4 vs 11.1 months; P < .0001) compared to controls. Median OS (44.3 vs 40.2 months) did not show a statistically significant benefit in the first line setting. However, in the second-line setting, with 380 propensity-matched-cohort, the palbociclib group had significantly longer PFS (10 vs 5 months, P < .0001) as well as OS (33 vs 24 months; P < .022), compared to controls. We conclude that in this single center analysis of a large cohort of metastatic HR+ HER2- BC patients, palbociclib in combination with ET was associated with improved PFS in both first-line and second-line settings and OS in the second-line setting compared to ET alone cohort.
MeSH term(s)	Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Breast Neoplasms/drug therapy ; Female ; Humans ; Piperazines ; Protein Kinase Inhibitors/therapeutic use ; Pyridines ; Receptor, ErbB-2 ; Receptors, Estrogen
Chemical Substances	Piperazines ; Protein Kinase Inhibitors ; Pyridines ; Receptors, Estrogen ; Receptor, ErbB-2 (EC 2.7.10.1) ; palbociclib (G9ZF61LE7G)
Language	English
Publishing date	2022-03-03
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	218257-9
ISSN	1097-0215 ; 0020-7136
ISSN (online)	1097-0215
ISSN	0020-7136
DOI	10.1002/ijc.33959
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 478: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 576: Show issues

Order via subito

Details ▾

Article ; Online: Development and validation of a multiplex immunoassay for the simultaneous quantification of type-specific IgG antibodies to E6/E7 oncoproteins of HPV16 and HPV18.

Layman, Hans / Rickert, Keith W / Wilson, Susan / Aksyuk, Anastasia A / Dunty, Jill M / Natrakul, Dusit / Swaminathan, Nithya / DelNagro, Christopher J

PloS one

2020 Volume 15, Issue 3, Page(s) e0229672

Abstract: More than 170 types of human papilloma viruses (HPV) exist with many causing proliferative diseases linked to malignancy in indications such as cervical cancer and head and neck squamous cell carcinoma. Characterization of antibody levels toward HPV ... ...

Abstract	More than 170 types of human papilloma viruses (HPV) exist with many causing proliferative diseases linked to malignancy in indications such as cervical cancer and head and neck squamous cell carcinoma. Characterization of antibody levels toward HPV serology is challenging due to complex biology of oncoproteins, pre-existing titers to multiple HPV types, cross-reactivity, and low affinity, polyclonal responses. Using multiplex technology from MSD, we have developed an assay that simultaneously characterizes antibodies against E6 and E7 oncoproteins of HPV16 and 18, the primary drivers of HPV-associated oncogenesis. We fusion tagged our E6 and E7 proteins with MBP via two-step purification, spot-printed an optimized concentration of protein into wells of MSD 96-well plates, and assayed various cynomolgus monkey, human and HPV+ cervical cancer patient serum to validate the assay. The dynamic range of the assay covered 4-orders of magnitude and antibodies were detected in serum at a dilution up to 100,000-fold. The assay was very precise (n = 5 assay runs) with median CV of human serum samples ~ 5.3% and inter-run variability of 11.4%. The multiplex serology method has strong cross-reactivity between E6 oncoproteins from human serum samples as HPV18 E6 antigens neutralized 5 of 6 serum samples as strongly as HPV16 E6. Moderate concordance (Spearman's Rank = 0.775) was found between antibody responses against HPV16 E7 in the multiplex assay compared to standard ELISA serology methods. These results demonstrate the development of a high-throughput, multi-plex assay that requires lower sample quantity input with greater dynamic range to detect type-specific anti-HPV concentrations to E6 and E7 oncoproteins of HPV16 and 18.
MeSH term(s)	Animals ; Antibodies, Viral/blood ; Antibody Specificity ; Cross Reactions ; DNA-Binding Proteins/immunology ; Electrochemical Techniques ; Enzyme-Linked Immunosorbent Assay ; Female ; High-Throughput Screening Assays/methods ; High-Throughput Screening Assays/statistics & numerical data ; Human papillomavirus 16/immunology ; Human papillomavirus 18/immunology ; Humans ; Immunoassay/methods ; Immunoassay/statistics & numerical data ; Immunoglobulin G/blood ; Limit of Detection ; Luminescent Measurements/methods ; Luminescent Measurements/statistics & numerical data ; Macaca fascicularis ; Oncogene Proteins, Viral/immunology ; Papillomavirus E7 Proteins/immunology ; Repressor Proteins/immunology ; Uterine Cervical Neoplasms/immunology ; Uterine Cervical Neoplasms/virology
Chemical Substances	Antibodies, Viral ; DNA-Binding Proteins ; E6 protein, Human papillomavirus type 16 ; E6 protein, Human papillomavirus type 18 ; E7 protein, Human papillomavirus type 18 ; Immunoglobulin G ; Oncogene Proteins, Viral ; Papillomavirus E7 Proteins ; Repressor Proteins ; oncogene protein E7, Human papillomavirus type 16
Language	English
Publishing date	2020-03-26
Publishing country	United States
Document type	Journal Article ; Validation Study
ISSN	1932-6203
ISSN (online)	1932-6203
DOI	10.1371/journal.pone.0229672
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer.

Yam, Clinton / Mittendorf, Elizabeth A / Garber, Haven R / Sun, Ryan / Damodaran, Senthil / Murthy, Rashmi K / Ramirez, David / Karuturi, Meghan / Layman, Rachel M / Ibrahim, Nuhad / Rauch, Gaiane M / Adrada, Beatriz E / Candelaria, Rosalind P / White, Jason B / Ravenberg, Elizabeth / Clayborn, Alyson / Ding, Qing Qing / Symmans, W Fraser / Prabhakaran, Sabitha /

Thompson, Alastair M / Valero, Vicente / Tripathy, Debu / Huo, Lei / Moulder, Stacy L / Litton, Jennifer K

Breast cancer research and treatment

2023 Volume 199, Issue 3, Page(s) 457–469

Abstract: Purpose: Neoadjuvant anti-PD-(L)1 therapy improves the pathological complete response (pCR) rate in unselected triple-negative breast cancer (TNBC). Given the potential for long-term morbidity from immune-related adverse events (irAEs), optimizing the ... ...

Abstract	Purpose: Neoadjuvant anti-PD-(L)1 therapy improves the pathological complete response (pCR) rate in unselected triple-negative breast cancer (TNBC). Given the potential for long-term morbidity from immune-related adverse events (irAEs), optimizing the risk-benefit ratio for these agents in the curative neoadjuvant setting is important. Suboptimal clinical response to initial neoadjuvant therapy (NAT) is associated with low rates of pCR (2-5%) and may define a patient selection strategy for neoadjuvant immune checkpoint blockade. We conducted a single-arm phase II study of atezolizumab and nab-paclitaxel as the second phase of NAT in patients with doxorubicin and cyclophosphamide (AC)-resistant TNBC (NCT02530489). Methods: Patients with stage I-III, AC-resistant TNBC, defined as disease progression or a < 80% reduction in tumor volume after 4 cycles of AC, were eligible. Patients received atezolizumab (1200 mg IV, Q3weeks × 4) and nab-paclitaxel (100 mg/m Results: From 2/15/2016 through 1/29/2021, 37 patients with AC-resistant TNBC were enrolled. The pCR/RCB-I rate was 46%. No new safety signals were observed. Seven patients (19%) discontinued atezolizumab due to irAEs. Conclusion: This study met its primary endpoint, demonstrating a promising signal of activity in this high-risk population (pCR/RCB-I = 46% vs 5% in historical controls), suggesting that a response-adapted approach to the utilization of neoadjuvant immunotherapy should be considered for further evaluation in a randomized clinical trial.
MeSH term(s)	Humans ; Female ; Anthracyclines/therapeutic use ; Triple Negative Breast Neoplasms/pathology ; Neoadjuvant Therapy ; Breast Neoplasms/drug therapy ; Paclitaxel/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
Chemical Substances	130-nm albumin-bound paclitaxel ; atezolizumab (52CMI0WC3Y) ; Anthracyclines ; Paclitaxel (P88XT4IS4D)
Language	English
Publishing date	2023-04-15
Publishing country	Netherlands
Document type	Randomized Controlled Trial ; Clinical Trial, Phase II ; Journal Article
ZDB-ID	604563-7
ISSN	1573-7217 ; 0167-6806
ISSN (online)	1573-7217
ISSN	0167-6806
DOI	10.1007/s10549-023-06929-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1655: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Adverse Childhood Experiences Associated with Greater Internalization of Weight Stigma in Women with Excess Weight.

Keirns, Natalie G / Tsotsoros, Cindy E / Addante, Samantha / Layman, Harley M / Krems, Jaimie Arona / Pearl, Rebecca L / Janet Tomiyama, A / Hawkins, Misty A W

Obesities

2021 Volume 1, Issue 1, Page(s) 49–57

Abstract: Adverse childhood experiences (ACEs) may be an early life factor associated with adult weight stigma via biological (e.g., stress response), cognitive (e.g., self-criticism/deprecation), and/or emotional (e.g., shame) mechanisms. This pilot study ... ...

Abstract	Adverse childhood experiences (ACEs) may be an early life factor associated with adult weight stigma via biological (e.g., stress response), cognitive (e.g., self-criticism/deprecation), and/or emotional (e.g., shame) mechanisms. This pilot study investigated relationships between ACEs and internalized and experienced weight stigma in adult women with overweight/obesity and explored differential relationships between weight stigma and ACE subtypes (i.e., abuse, neglect, household dysfunction). Adult women (68% white,
Language	English
Publishing date	2021-06-03
Publishing country	Switzerland
Document type	Journal Article
ISSN	2673-4168
ISSN (online)	2673-4168
DOI	10.3390/obesities1010005
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research

2023 Volume 30, Issue 2, Page(s) 334–343

Abstract: Purpose: Endocrine-based therapy is the initial primary treatment option for hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC). However, patients eventually experience disease ... ...

Abstract	Purpose: Endocrine-based therapy is the initial primary treatment option for hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC). However, patients eventually experience disease progression due to resistance to endocrine therapy. Molibresib (GSK525762) is a small-molecule inhibitor of bromodomain and extraterminal (BET) family proteins (BRD2, BRD3, BRD4, and BRDT). Preclinical data suggested that the combination of molibresib with endocrine therapy might overcome endocrine resistance. This study aimed to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy [objective response rate (ORR)] of molibresib combined with fulvestrant in women with HR+/HER2- mBC. Patients and methods: In this phase I/II dose-escalation and dose-expansion study, patients received oral molibresib 60 or 80 mg once daily in combination with intramuscular fulvestrant. Patients enrolled had relapsed/refractory, advanced/metastatic HR+/HER2- breast cancer with disease progression on prior treatment with an aromatase inhibitor, with or without a cyclin-dependent kinase 4/6 inhibitor. Results: The study included 123 patients. The most common treatment-related adverse events (AE) were nausea (52%), dysgeusia (49%), and fatigue (45%). At a 60-mg dosage of molibresib, >90% of patients experienced treatment-related AE. Grade 3 or 4 treatment-related AE were observed in 47% and 48% of patients treated with molibresib 60 mg and molibresib 80 mg, respectively. The ORR was 13% [95% confidence interval (CI), 8-20], not meeting the 25% threshold for proceeding to phase II. Among 82 patients with detected circulating tumor DNA and clinical outcome at study enrollment, a strong association was observed between the detection of copy-number amplification and poor progression-free survival (HR, 2.89; 95% CI, 1.73-4.83; P < 0.0001). Conclusions: Molibresib in combination with fulvestrant did not demonstrate clinically meaningful activity in this study.
MeSH term(s)	Humans ; Female ; Breast Neoplasms/drug therapy ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Fulvestrant ; Nuclear Proteins ; Receptor, ErbB-2/metabolism ; Transcription Factors ; Disease Progression ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bromodomain Containing Proteins ; Cell Cycle Proteins ; Benzodiazepines
Chemical Substances	Fulvestrant (22X328QOC4) ; molibresib (5QIO6SRZ2R) ; Nuclear Proteins ; Receptor, ErbB-2 (EC 2.7.10.1) ; Transcription Factors ; BRD4 protein, human ; Bromodomain Containing Proteins ; Cell Cycle Proteins ; Benzodiazepines (12794-10-4)
Language	English
Publishing date	2023-11-22
Publishing country	United States
Document type	Clinical Trial, Phase I ; Clinical Trial, Phase II ; Journal Article
ZDB-ID	1225457-5
ISSN	1557-3265 ; 1078-0432
ISSN (online)	1557-3265
ISSN	1078-0432
DOI	10.1158/1078-0432.CCR-23-0133
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4223: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Histone deacetylase inhibition protects hearing against acute ototoxicity by activating the Nf-

Layman, W S / Williams, D M / Dearman, J A / Sauceda, M A / Zuo, J

Cell death discovery

2015 Volume 1

Abstract: Auditory hair cells have repeatedly been shown to be susceptible to ototoxicity from a multitude of drugs including aminoglycoside antibiotics. Here, we found that systemic HDAC inhibition using suberoylanilide hydroxamic acid (SAHA) on adult mice offers ...

Abstract	Auditory hair cells have repeatedly been shown to be susceptible to ototoxicity from a multitude of drugs including aminoglycoside antibiotics. Here, we found that systemic HDAC inhibition using suberoylanilide hydroxamic acid (SAHA) on adult mice offers almost complete protection against hair cell loss and hearing threshold shifts from acute ototoxic insult from kanamycin potentiated with furosemide. We also found that the apparent lack of hair cell loss was completely independent of spontaneous or facilitated (ectopic
Language	English
Publishing date	2015-07-31
Publishing country	United States
Document type	Journal Article
ISSN	2058-7716
ISSN	2058-7716
DOI	10.1038/cddiscovery.2015.12
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED